Products

Therapeutic Protein/Peptide Component:

Indication(s): 

Owner

Key Attributes:

Development Status:

• Sustained serum levels within therapeutic range for minimum of 2 weeks
• Lower peak/trough ratio than other approaches (e.g. depots)
• Safety profile expected to be comparable to approved product
• Stable liquid small volume injection (27-30 G needle) administered with autoinjector

• Preclinical studies completed in rats and monkeys
• Pharmacokinetics in rats and monkeys
• Proof of concept efficacy in hypophysectomized rat model
• Pharmacodynamics (IGF-I responses) in monkeys (repeat dose)